IMA - NASDAQ

ImageneBio Inc

IMA·NASDAQ

$5.69

+2.3%

HealthcareBiotechnology

Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis

Statements Value Model

At a Glance

Live Snapshot

Market Cap$64.18M

EPS-10.7600

P/E Ratio-0.53

Earnings Date07/23/2026

ima

Net Debt

Last Annual Value

-24.97M

3-Year CAGR

23%

5-Year CAGR

31%

10-Year CAGR

-5%

Adjust for Inflation

ImageneBio Inc Competitors Analysis of Net Debt

IMA · NASDAQ

Company	Net Debt	CAGR 3Y	CAGR 5Y	CAGR 10Y
ImageneBio Inc NASDAQ:IMA	-24.97M	N/A	N/A	N/A
Quince Therapeutics, Inc. NASDAQ:QNCX	8.60M	N/A	N/A	N/A
Adicet Bio, Inc. NASDAQ:ACET	-24.18M	N/A	N/A	N/A
MindWalk Holdings Corp. NASDAQ:HYFT	2.74M	N/A	N/A	N/A
Immunic, Inc. NASDAQ:IMUX	-14.80M	N/A	N/A	N/A
Nutriband Inc. NASDAQ:NTRB	-4.12M	N/A	N/A	N/A
Unicycive Therapeutics, Inc. NASDAQ:UNCY	-29.08M	N/A	N/A	N/A
Vaxart, Inc. NASDAQ:VXRT	-44.83M	N/A	N/A	N/A
Sutro Biopharma, Inc. NASDAQ:STRO	-42.46M	N/A	N/A	N/A
Ovid Therapeutics Inc. NASDAQ:OVID	266.00K	N/A	N/A	N/A
Kalaris Therapeutics Inc NASDAQ:KLRS	-96.61M	N/A	N/A	N/A

ImageneBio Inc Fair Value Envelope

IMA · NASDAQ

Our analysis suggests that IMA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5.69, this represents a potential HIDDEN relative to our calculated worth for ImageneBio Inc.

HIDDEN

Intrinsic Value

Current Price: $5.69

Related Guides

Blog Categories

Continue your IMA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.